Nephros Financial Statements From 2010 to 2022

NEPH
 Stock
  

USD 1.50  0.03  1.96%   

Nephros financial statements provide useful quarterly and yearly information to potential Nephros investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nephros financial statements helps investors assess Nephros' valuation, profitability, and current liquidity needs.
Nephros does not presently have any fundamental ratios for analysis.
.
  
Refresh
Check Nephros financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nephros main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Nephros financial statements analysis is a perfect complement when working with Nephros Valuation or Volatility modules. It can also supplement various Nephros Technical models. Additionally, see the analysis of Nephros Correlation against competitors.

Nephros Total Debt Analysis

Nephros' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Total Debt 
 = 
Bonds 
+  
Notes 
More About Total Debt | All Equity Analysis

Current Nephros Total Debt

    
  1.12 M  
Most of Nephros' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nephros is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Compare to competition

Based on the latest financial disclosure, Nephros has a Total Debt of 1.12 M. This is 99.96% lower than that of the Healthcare sector and 99.9% lower than that of the Medical Instruments & Supplies industry. The total debt for all United States stocks is 99.98% higher than that of the company.

Nephros Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Nephros's current stock value. Our valuation model uses many indicators to compare Nephros value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nephros competition to find correlations between indicators driving Nephros's intrinsic value. More Info.
Nephros is considered to be number one stock in debt to equity category among related companies. It is considered to be number one stock in market capitalization category among related companies creating about  201,973,684  of Market Capitalization per Debt to Equity. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nephros by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nephros' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nephros' earnings, one of the primary drivers of an investment's value.

About Nephros Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Nephros income statement, its balance sheet, and the statement of cash flows. Nephros investors use historical funamental indicators, such as Nephros's revenue or net income, to determine how well the company is positioned to perform in the future. Although Nephros investors may use each financial statement separately, they are all related. The changes in Nephros's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nephros's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Nephros Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Nephros. Please read more on our technical analysis and fundamental analysis pages.
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nephros without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Nephros using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Nephros Correlation against competitors. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Nephros Stock analysis

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
15.8 M
Quarterly Revenue Growth YOY
-0.2
Return On Assets
-0.2
Return On Equity
-0.37
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine Nephros value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.